Research
BNP Paribas Upgrades Genmab to Outperform, Boosts PT
BNP Paribas on Wednesday upgraded Danish healthcare company Genmab (GMAB.CO) to outperform from neutral and increased its price target to 2,400 Danish kroner from 1,300 kroner.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$GMAB.CO
